Navigation Links
Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy
Date:12/15/2010

ortance being placed on accelerating the development of drugs like this in order to reach the patients in need as quickly as possible."  Ocera plans to initiate Phase 2 studies in 2011.

OCR-002 data presented at EASL, AASLD, and ISHEN in 2010 have confirmed that OCR-002 can consistently lower ammonia in multiple preclinical models of cirrhosis and acute liver failure and has been correlated with normalization of intracranial pressure, brain edema and neurologic function.

"OCR-002 is a promising new therapy for the acute care of patients with hyperammonemia and hepatic encephalopathy, a patient population for whom treatment options are currently very limited," stated Dr. Tarek Hassanein, Professor of Medicine and Director of Southern California Liver Centers, Coronado, CA.

About OCR-002

OCR-002 (ornithine phenylacetate) is a novel injectable treatment with a unique mechanism of action that directly reduces toxic levels of ammonia in the blood. When the liver is unable to detoxify ammonia, patients are at risk of developing hepatic encephalopathy, a condition that can lead to coma and death, requiring hospitalization that cost the U.S. healthcare system $1.2 billion every year. The compound has demonstrated in several published studies that it has a rapid and sustained effect in lowering toxic ammonia levels and can prevent severe neurologic complications in animal models of acute liver failure and liver cirrhosis.  Ocera Therapeutics licensed OCR-002 from University College of London in December 2008.

About Hepatic Encephalopathy

Hepatic Encephalopathy (HE) is caused by the accumulation of toxic substances in the bloodstream, including ammonia, that are normally removed by the liver.  HE ranges in severity from disorientation to confusion, coma and even death.  With severe liver impairment, toxic substances such as ammonia accumulate in the blood and impair the function of brain cells.  
'/>"/>

SOURCE Ocera Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
2. Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting
3. Dr Stephan Rietiker Joins BioCeramic Therapeutics
4. Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman
5. Talecris Biotherapeutics Announces Jury Verdict in Contract Dispute
6. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
7. Reportlinker Adds Global Bladder Cancer Therapeutics Industry
8. Intarcia Therapeutics Executive Chairman, Kurt Graves to Present at Lazard Capital Markets 7th Annual Healthcare Conference
9. Argos Therapeutics to Present Corporate Overview and Next Steps in Clinical Development of Arcelis™ Immunotherapy at Lazard Capital Markets 7th Annual Healthcare Conference
10. Silence Therapeutics Lead RNA Interference Therapeutic Prevents Spread of Cancer to Lungs
11. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... 17, 2015  US-Australian drug discovery company, Novogen, today ... Understanding with the Feinstein Institute for Medical Research ... to collaborate with the objective of developing ... collaboration brings together the drug discovery expertise of ... the Feinstein Institute in neurosciences and oncology. ...
(Date:4/17/2015)... BellBrook Labs announced today that they ... powerful Orthogonal Pooled Screening (OPS) Platform developed and ... Lankenau Institute for Medical Research (LCGC) in Wynnewood, ... successful drug discovery outcomes using far more efficient ... available nowhere else, coupled to a state-of-the-art compound ...
(Date:4/16/2015)... 16, 2015 Cambridge Semantics ... driven by Semantic Web technology, and Informa ... and services for the academic and scientific, professional ... joint solution ‘Smart Data Lake for Clinical Trial ... the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... Proove Biosciences , Inc. is pleased ... for the 2015 BIO International Convention. Hosted by ... Convention will take place June 15-18 at the Pennsylvania ... BIO contest, industry leaders will be voting for companies ... The community voting period began on April 14, 2015 ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3
... was one of the hottest topics among both attendees ... Friday at the Medical College of Wisconsin (MCW) ... the right info at the right time in the ... consultant with the Wisconsin Department of Administration , ...
... World Health Organization has laid down an urgent challenge ... to nicotine addiction, and the planet will be a ... former U.S. ambassador to Norway and the former Speaker ... to last weeks Wisconsin Life Sciences & Venture Conference ...
... Norlight Telecommunications , a Wisconsin-based provider of integrated data ... center in their recently built Wisconsin headquarters. The 4200 ... new 13,000-square-foot technology facility that includes a network management ... new headquarters. The data center is also used for ...
Cached Biology Technology:Standards Needed for Advances in Healthcare Technology 2Standards Needed for Advances in Healthcare Technology 3Standards Needed for Advances in Healthcare Technology 4AIDS and tobacco are worldwide killers: Is bioscience doing enough to stop them? 2
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
(Date:4/2/2015)... , April 2, 2015 ... tests DERMALOG by far outperforms the strongest competitors, ... maintaining high accuracy, the system is capable of ... the speed proves up to be ten times ... than its runner-up performance.      (Photo: ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... MDA new report appearing in the September issue of ... that significant muscle loss is unavoidable when losing weight through ... twice the recommended daily allowance (RDA) of protein while adhering ... muscle mass and promotes fat loss. Tripling the RDA of ...
... Bethesda, MDNot only do statins extend lives by lowering cholesterol ... research in the September 2013 issue of The ... as well. Specifically, statins may reduce the rate at which ... This opens the door for using statins, or derivatives of ...
... clingy people, but "clingy" blood platelets may offer hope ... new research findings published in The Journal ... immune cells (lymphocytes) known to play a significant role ... Those attached platelets reduced the ability of the immune ...
Cached Biology News:Doubling the daily allowance of protein intake with diet and exercise protects muscle loss 2Clingy platelets suggest potential treatment strategy for rheumatoid arthritis 2
See product name for description....
2'-Fluorine-CTP (2'-F-CTP) is readily incorporated into transcripts by T7 and SP6 R&DNA™ Polymerase and is available separately....
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Human Contactin-2/TAG1 Affinity Purified Polyclonal Ab...
Biology Products: